You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 5,766,603


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,766,603
Title: Cell culture of hepatitis A virus
Abstract:Hepatitis A virus is attenuated in virulence by in vitro passage in susceptible cell cultures, without prior passage in a subhuman primate. This process results in a live, attenuated hepatitis A virus vaccine suitable for human disease prevention.
Inventor(s): Giesa; Paula A. (Lansdale, PA), Provost; Philip J. (Lansdale, PA), Hilleman; Maurice R. (Lafayette Hill, PA)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:08/458,196
Patent Claims:1. Propagated hepatitis A virus, not previously passaged in a non-human primate, propagated by cell culture of hepatitis A virus in (i) primary, continuously cultivated, or transformed cells derived from kidney or liver tissue of human or non-human primate origin; and/or (ii) diploid fibroblast cells derived from human or non-human primate lung tissue; the inoculum for the cell culture being either a hepatitis A virus inoculum derived from a human clinical specimen or an inoculum from a hepatitis A virus passaged cell culture whose initial cell culture inoculum was a hepatitis A virus inoculum derived from a human clinical specimen.

2. Propagated hepatitis A virus according to claim 1 wherein the propagated virus is capable of inducing a protective immune response in humans against hepatitis A disease without causing significant symptoms of hepatitis A disease.

3. A vaccine comprising propagated hepatitis A virus according to claim 2.

4. Propagated hepatitis A virus according to claim 2 which has been inactivated after propagation.

5. A vaccine comprising propagated hepatitis A virus according to claim 4.

6. A Propagated hepatitis A virus, not previously passaged in a non-human primate, propagated by sequential passage comprising hepatitis A virus, in a first passage stage comprising primary, continuously cultivated, or transformed cells derived from kidney or liver tissue of human or non-human primate origin; and in a second passage stage comprising diploid fibroblast cells derived from human or non-human primate lung tissue; the inoculum for which was a hepatitis A virus inoculum derived from a human clinical specimen or an inoculum from a hepatitis A virus passaged cell culture whose initial cell culture inoculum was a hepatitis A virus inoculum derived from a human clinical specimen.

7. Propagated hepatitis A virus according to claim 6, in which the first passage stage is in kidney cells of fetal or newborn rhesus, cynomolgus, or cercopithecus monkey origin.

8. Propagated hepatitis A virus according to claim 7 in which the first passage stage is in FRhK6 cells.

9. Propagated hepatitis A virus according to claim 6 in which the second passage stage is in WI-38 or MRC-5 cells.

10. Propagated hepatitis A virus according to claim 6 in which the virus is capable of inducing a protective immune response in humans against hepatitis A disease without causing significant symptoms of hepatitis A disease.

11. A vaccine comprising propagated hepatitis A virus according to claim 10.

12. Propagated hepatitis A virus according to claim 10 which has been inactivated after propagation.

13. A vaccine comprising propagated hepatitis A virus according to claim 12.

14. A cell culture comprising hepatitis A virus in (i) primary, continuously cultivated, or transformed cells derived from kidney or liver tissue of human or non-human primate origin; or in (ii) diploid fibroblast cells derived from human or non-human primate lung tissue; the inoculum for which was a hepatitis A virus inoculum derived from a human clinical specimen without passage in a non-human primate host or an inoculum from a hepatitis A virus passaged cell culture whose initial cell culture inoculum was a hepatitis A virus inoculum derived from a human clinical specimen without passage in a non-human primate host.

15. An infected cell culture harvest comprising hepatitis A virus which was propagated in a cell culture of (i) primary, continuously cultivated, or transformed cells derived from kidney or liver tissue of human or non-human primate origin; or (ii) diploid fibroblast cells derived from human or non-human primate lung tissue; using as an inoculum a hepatitis A virus inoculum derived from a human clinical specimen without passage in a non-human primate host or an inoculum from a hepatitis A virus passaged cell culture whose initial cell culture inoculum was a hepatitis A virus inoculum derived from a human clinical specimen without passage in a non-human primate host.

16. A hepatitis A vaccine comprising attenuated, inactivated hepatitis A virus from a cell culture of (i) primary, continuously cultivated, or transformed cells derived from kidney or liver tissue of human or non-human primate origin; or (ii) diploid fibroblast cells derived from human or non-human primate lung tissue; wherein the hepatitis A virus had not been passaged through a non-human primate prior to cell culture.

17. A process for making a hepatitis A vaccine which comprises:

a) culturing hepatitis A virus, which has not been passaged through a non-human primate in (i) primary, continuously cultivated, or transformed cells derived from kidney or liver tissue of human or non-human primate origin; or in (ii) diploid fibroblast cells derived from human or non-human primate lung tissue;

b) harvesting the cultured hepatitis A virus; and

c) inactivating the harvested hepatitis A virus to make a vaccine.

18. A hepatitis A vaccine comprising hepatitis A virus passaged in a first passage stage comprising 5 passages in cell culture of primary, continuously cultivated, or transformed cells derived from kidney or liver tissue of human or non-human primate origin; or (ii) diploid fibroblast cells derived from human or non-human primate lung tissue; wherein the hepatitis A virus was not passaged through a non-human primate prior to cell culture.

19. A vaccine according to claim 18 wherein the hepatitis A virus has been propagated in cell culture in a first passage stage comprising about 5 to about 25 cell culture passages of said hepatitis A virus from a human clinical specimen, comprising hepatitis A virus in primary, continuously cultivated, or transformed cells derived from kidney or liver tissue of human or non-human primate origin; followed by a second passage stage comprising at least about 5 cell culture passages in diploid fibroblast cells derived from human or non-human primate lung tissue.

20. A process for making an inactivated HAV vaccine which comprises:

a) culturing hepatitis A virus, which has not been passaged through a non-human primate in a first passage stage comprising about 5 to about 25 passages in a non-human primate kidney or liver cells and a second passage stage comprising about 5 to about 50 passsages in human or non-human lung fibroblast cells;

b) harvesting the cultured hepatitis A virus; and

c) inactivating the harvested hepatitis A virus to make a vaccine.

21. Propagated hepatitis A virus, not previously passaged in a non-human primate, propagated by cell culture passage of hepatitis A virus in: (i) primary, continuously cultivated, or transformed cells derived from kidney or liver of non-human primate origin; and (ii) diploid fibroblast cells derived from human lung tissue; the inoculum for which was a hepatitis A inoculum from a human clinical specimen comprising hepatitis A virus or an inoculum from a hepatitis A virus passaged cell culture whose initial cell culture inoculum was a hepatitis A virus inoculum derived from a human clinical specimen.

22. Propagated hepatitis A virus of claim 21 in which the propagated virus is capable of inducing a protective immune response in humans against hepatitis A disease without causing significant symptoms of hepatitis A disease.

23. A vaccine comprising propagated hepatitis A virus according to claim 22.

24. Propagated hepatitis A virus according to claim 22 which has been inactivated after propagation.

25. A vaccine comprising propagated hepatitis A virus according to claim 24.

26. Propagated hepatitis A virus according to claim 22 in which the first passage stage is in kidney cells of fetal or newborn rhesus, cynomologus, or cercopithecus monkey origin.

27. Propagated hepatitis A virus according to claim 26 in which the first passage stage is in cells of cercopithecus monkey origin.

28. Propagated hepatitis A virus according to claim 26 in which the first passage stage is in FRhK6 cells.

29. The propagated hepatitis A virus of claim 21 further comprising a second passage stage in diploid fibroblast cells derived from human embryonic lung tissue.

30. The propagated hepatitis A virus according to claim 29 in which the second passage stage is in WI-38 or MRC-5 cells.

31. Propagated hepatitis A virus, having been previously propagated in cell culture, said virus not having been passaged in a non-human primate, wherein said virus was propagated by cell culture in: (i) primary, continuously cultivated, or transformed cells derived from kidney or liver tissue of non-human primate origin; and (ii) diploid fibroblast cells derived from human lung tissue.

32. Propagated hepatitis A virus according to claim 31 in which the propagated virus is capable of inducing a protective immune response in humans against hepatitis A disease without causing significant symptoms of hepatitis A disease.

33. A vaccine comprising the propagated hepatitis A virus according to claim 32.

34. Propagated hepatitis A virus according to claim 33 which has been inactivated after propagation.

35. A vaccine comprising propagated hepatitis A virus according to claim 34.

36. A cell culture of hepatitis A virus, wherein the hepatitis A virus had been previously propagated in: (i) primary, continuously cultivated, or transformed cells derived from kidney or liver tissue of non-human primate origin; and (ii) in diploid fibroblast cells derived from human lung tissue, wherein the inoculum for (i) was a hepatitis A virus inoculum derived from a human clinical specimen without passage in a non-human primate host or an inoculum from a hepatitis A virus passaged cell culture whose initial cell culture inoculum was a hepatitis A virus inoculum derived from a human clinical specimen.

37. Propagated virus according to claim 1 wherein the human clinical specimen is a stool extract.

38. Propagated virus according to claim 6 wherein the human clinical specimen is a stool extract.

39. Propagated virus according to claim 21 wherein the human clinical specimen is a stool extract.

40. Propagated virus according to claim 31 wherein the human clinical specimen is a stool extract.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.